Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas

Abstract

To assess the effect of dienogest on recurrence of ovarian endometriomas and severity of pain after laparoscopic surgery, a retrospective study of 81 patients was performed at three institutions in Osaka, Japan. Patients had a six-month minimum follow-up after laparoscopic surgery for ovarian endometriomas performed between June 2012 and August 2014. Patients who chose to receive 2 mg dienogest daily and those who were managed expectantly postoperatively were included. Recurrence was defined as the presence of endometriomas of more than 2 cm. A visual analog scale (VAS) was used to score the intensity of pelvic pain. The cumulative recurrence rate and absolute VAS score changes between the baseline and at 6, 12, 18 and 24 months after the start of administration were evaluated in both groups. The recurrence rate was 16.5% and 24.0% in the expectant management group at 12 and 24 months, respectively. No recurrences occurred in the dienogest treatment group. The rate of VAS score reduction was significantly higher in the dienogest than in the expectant management group. Dienogest is effective on the recurrence of ovarian endometrioma and relieving pelvic pain after laparoscopic surgery.

Chinese abstract

为评估地诺孕素对卵巢子宫内膜异位囊肿患者腹腔镜手术后抑制复发和缓解严重疼痛的效果。回顾性分析了来自日本大阪三个机构的81例患者, 对2012年6月至2014年8月期间行腹腔镜手术治疗的卵巢子宫内膜异位囊肿患者进行为期至少六个月的随访。包括选择每天接受2 mg地诺孕素的患者和术后期待处理的患者。子宫内膜异位囊肿出现超过2 cm者为复发。用视觉模拟量表（VAS）评分盆腔疼痛的强度。在两组群体中, 累计复发率和VAS评分在基线与干预后6、12、18、24个月进行评估。在期待管理组12和24个月的复发率分别为16.5%和24.0%。在地诺孕素治疗组没有出现复发。VAS评分减分率在地诺孕素组明显高于期待处理组。地诺孕素对减少卵巢子宫内膜异位囊肿的复发和缓解腹腔镜手术后盆腔疼痛是有效的。

• Dienogest
• laparoscopic surgery
• ovarian endometrioma

Declaration of interest

The authors report no conflicts of interest.